ACTPrecis™ GI

Precision Medicine To Orchestrate A Treatment Strategy Based On Core Genes

Seizes Opportunities in Late-Stage Treatment

In the history of cancer treatment, precision medicine is now endorsed as a modern and preferred way for a healthcare system to take care of its cancer patients. Challenges in identifying the right drug for every cancer patient, as new drugs are emerging for specific genomic mutations, can be tackled strategically by obtaining a cancer patient's unique cancer genomic profile. The acceleration of oncology drug approvals and the modernization of clinical trials with biomarker-based patients have progressed well, as these have been commitments of the US FDA from 2018. The wave of precision medicine has also increased the approvals of companion diagnostics, which has resulted in ACT Genomics' genomic profiling service being on the waiting list for US FDA approval.

Why You Need to Know About Precision Medicine

The top global pharma companies are increasingly conducting clinical trials using precision medicine, which requires a cancer patient's genomic information through genomic profiling. This evolution has been felt by most hospitals, so it is increasingly more likely that genomic profiling will be required if you wish to try a new treatment option.

How to Ensure Your Treatment is Aimed at the Bull's Eye

Metastatic colorectal cancer genomic profiling enables major targets to be revealed all at once, such as KRAS, NRAS, BRAF, ERBB2, etc, and then by identifying the driver oncogenes, you will be aiming at the bull's eye and increase the chances of having a successful treatment.

Gastrointestinal Stromal Tumors (GIST) patients harbour various genomic mutations in KIT and PDGFRα gene. Genomic testing guides the selection of targeted therapies for GIST patients.

Common Problems in Cancer Treatment

∙ Chemotherapy and surgery are the only options recommended by the NCCN guidelines or single-gene testing results.
∙ Complications and metastases make it difficult to determine an appropriate drug.
∙ Ineffective treatment and cancer relapse after targeted therapy.

Diagnostic Solutions for Various Cancers

Through DNA+RNA next-generation sequencing (NGS), ACTPrecis^TM GI targeted genomic profiling decodes 10 actionable cancer genes (including 3 fusion genes) to map drug options based on NCCN Guideline and FDA approved therapeutic options. As single gene testing only provides very limited results, NGS genomic profiling can detect any special genomic mutations to result in a more effective treatment; if recurrence or metastases are found, treatment can be modified according to the NGS genomic profiling result to overcome drug resistance.

Treatment Advantages from ACTPrecis™ GI 

✔ More humane process: Avoids multiple biopsies and the time cost associated with single-gene testing, as only a small specimen is required for the simultaneous detection of various fusion genes.

✔ More ideal treatment: Nominates proper targeted options.

✔ More intelligent budgeting: Evaluates options before treatment, according to genomic information, to ensure success rate and avoid wasting of funds.

Type of patients
Metastatic colorectal cancer
Gastrointestinal Stromal Tumors (GIST) 

Specimen requirements
Tumor tissue (FFPE)

Turnaround time 
8 working days*

*starting from the date of receipt of approved samples at our CAP-accredited laboratory